Healthcare of Ontario Pension Plan Trust Fund Purchases Shares of 35,950 Hims & Hers Health, Inc. $HIMS

Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,950 shares of the company’s stock, valued at approximately $746,000.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new position in shares of Hims & Hers Health in the 4th quarter worth about $11,187,000. Cunning Capital Partners LP purchased a new position in Hims & Hers Health during the 4th quarter valued at about $1,110,000. Virtu Financial LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at about $1,937,000. Finally, Norges Bank bought a new stake in Hims & Hers Health during the fourth quarter worth about $62,153,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $27.79 on Monday. The company has a market cap of $6.43 billion, a price-to-earnings ratio of -308.74, a P/E/G ratio of 78.15 and a beta of 2.40. The business’s fifty day simple moving average is $31.23 and its two-hundred day simple moving average is $26.08. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider owned 181,861 shares in the company, valued at approximately $6,365,135. This trade represents a 11.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is owned by company insiders.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: One bullish analysis argues that Hims & Hers remains undervalued, citing projected revenue growth, approximately 73% gross margins, accelerating subscriber additions, GLP-1 and peptide demand, international expansion, and the Novo Nordisk partnership. The thesis suggests substantial long-term upside if the company sustains growth despite the regulatory controversy. Hims & Hers Health: Still an Undervalued Company With Tremendous Upside
• Neutral Sentiment: Several law firms, including SBS Law, Kaplan Fox, Howard G. Smith, and Holzer & Holzer, announced investigations into possible securities-law violations. These announcements are typically investor-solicitation notices and do not establish wrongdoing, but they raise the possibility of shareholder litigation and additional disclosure obligations. SBS Law Investigation
• Negative Sentiment: The FTC alleges Hims & Hers shared customers’ health information with advertising platforms including Meta and Snap, failed to clearly disclose prescription charges, and used potentially deceptive billing and privacy practices. The lawsuit could lead to penalties, higher compliance expenses, tighter restrictions on marketing, and damage to consumer trust. Media coverage of the action contributed to a sharp decline in the shares and remains the principal near-term risk for HIMS. FTC Sues Hims & Hers

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HIMS. Needham & Company LLC raised their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Barclays upped their price target on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. Bank of America lifted their price objective on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research note on Thursday, July 9th. Finally, BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $31.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.